A lipid nanoparticle (LNP) is a tiny, spherical delivery system made of specially designed fats (lipids) that can safely transport fragile genetic material—like messenger RNA (mRNA)—into cells. Because naked mRNA is easily degraded by enzymes in the body and cannot cross cell membranes on its own, LNPs act as both a protective shield and a delivery vehicle.
Structurally, LNPs are not simple “bubbles,” but carefully engineered assemblies of four main components: ionizable lipids, phospholipids, cholesterol, and PEGylated lipids. The ionizable lipid is the key functional ingredient—it can switch charge depending on pH. At acidic pH during formulation, it becomes positively charged and binds tightly to negatively charged mRNA, helping encapsulate it. At physiological pH (~7.4), it becomes neutral, reducing toxicity in the bloodstream.
Once injected into the body (for example, via intramuscular injection in vaccines), LNPs circulate and are taken up by cells through endocytosis, a natural process where cells engulf external particles into vesicles called endosomes. At this stage, the mRNA is still trapped inside the endosome, and escape is critical for success.
This is where the chemistry of LNPs becomes especially clever. As the endosome matures, its internal environment becomes more acidic. The ionizable lipids regain a positive charge, which allows them to interact strongly with negatively charged lipids in the endosomal membrane. This interaction destabilizes the membrane, leading to endosomal escape—a process where the LNP disrupts the vesicle and releases the mRNA into the cytoplasm.
Once in the cytoplasm, the mRNA can finally do its job. It is recognized by the cell’s ribosomes, which translate the genetic code into a specific protein. In the case of COVID-19 vaccines, this protein is a viral spike protein that trains the immune system. In emerging cancer therapies, the mRNA may encode tumor antigens or therapeutic proteins.
